INVECTYS, INC. TO PARTICIPATE IN THE 41st JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023
05 janv. 2023 08h00 HE
|
Invectys, Inc.
Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of...
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
07 nov. 2022 08h45 HE
|
SciSparc Ltd
Meets primary endpoints- SCI-110 administration was found to be safe at all tested dosesSCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication...
Imunon Appoints James E. Dentzer to its Board of Directors
03 oct. 2022 17h00 HE
|
Imunon, Inc.
CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug...
Imunon Reports Partial Results from Ongoing Non-human Primate Study
03 oct. 2022 08h00 HE
|
Imunon, Inc.
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
29 sept. 2022 17h00 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes
22 sept. 2022 07h46 HE
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
12 sept. 2022 18h30 HE
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief...
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
07 sept. 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, FL, Sept. 07, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical- stage immunology company focused on developing treatments that harness the patient’s immune system to fight...
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy
06 sept. 2022 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
06 sept. 2022 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th...